Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2450 + anlotinib versus sunitinib for advanced renal cell carcinoma
CTR20201133Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib, sunitinib in renal cell carcinoma (RCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2020; status: completed.
02
Drugs
benmelstobartanlotinibsunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on CTR20201133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201133.